Related Experiment Video
Updated: Aug 20, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle
Lene Simonsen1, Gert Høy, Erik Didriksen
1Pharmaceutical Development, LEO Pharma, Ballerup, Denmark. lene.simonsen@leo-pharma.com
Abstract:
Calcipotriol and betamethasone dipropionate are widely used effective treatments for psoriasis. Combined therapy is known to be superior to monotherapy, but current formulations do not permit simultaneous application as the drug substances will degrade when mixed. The purpose of the study was to develop a formulation which combines calcipotriol and betamethasone dipropionate in a single vehicle hereby achieving optimal delivery of both substances into the skin. As the two substances are incompatible in aqueous and alcoholic medias, different non-aqueous formulations were prepared. Skin permeation studies were investigated using Franz-type diffusion cells. Formulations based on isopropyl myristate were found to decrease the permeation rate (25-35%) as compared with marketed monotherapy products (set to 100%). Lanolin had no overall effect on skin permeability. However, polyoxypropylene-15 stearyl ether (PSE) had a marked effect. A 5% PSE formulation resulted in a permeation rate comparable to the marketed products. Thus, by using PSE as solvent, it was possible to combine calcipotriol and betamethasone dipropionate in a single formulation while optimal skin permeability was attained. Recently, the efficiency of this formulation (Daivobet) has been verified in clinical studies showing an improved efficacy in the treatment of psoriatic patients.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Clinically Relevant Drug Product Specifications: Methods of Establishment
IV Infusion to Oral Dosing: Conversion Methods
Biopharmaceutics and Pharmacokinetics: Overview
Dosage Regimens: Designs and Approaches
Modified-Release Drug Delivery Systems: Site-Targeted
